- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Nasus Pharma stock reiterated at Market Outperform by Citizens | 1 | Investing.com | ||
| Mi | Nasus Pharma: Citizens bestätigt "Market Outperform" nach Studienfortschritt | 4 | Investing.com Deutsch | ||
| Di | Nasus Pharma, Ltd.: Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron | 170 | GlobeNewswire (Europe) | TEL AVIV, Israel, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative... ► Artikel lesen | |
| NASUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 14.09. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 14.09. | Nasus Pharma, Ltd.: Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis | 312 | GlobeNewswire (Europe) | Clinical study to evaluate NS002, the Company's investigational intranasal epinephrine powder, as a needle-free alternative to EpiPen® for patients experiencing anaphylaxis and will compare self-administration... ► Artikel lesen | |
| 04.09. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 19.08. | Nasus Pharma Targets Q4 Pivotal Study For Intranasal Epinephrine In $2 Billion Market, With Topline Data Expected Q1 2027 | 1 | pulse2.com | ||
| 19.08. | Nasus Pharma CFO Eyal Rubin to depart in September | 1 | Investing.com | ||
| 19.08. | Nasus Pharma CFO Eyal Rubin to leave | 2 | Seeking Alpha | ||
| 19.08. | Nasus Pharma, Ltd.: Nasus Pharma Announces Transition of Chief Financial Officer | 347 | GlobeNewswire (Europe) | TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE American: NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development... ► Artikel lesen | |
| 17.08. | Nasus Pharma 1H non-GAAP EPS of -$0.54 | 3 | Seeking Alpha | ||
| 17.08. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 17.08. | Nasus Pharma, Ltd.: Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update | 491 | GlobeNewswire (Europe) | Appointed Pharma Industry Veteran Brendan O'Grady as Chief Executive Officer Company on Track to Advance Clinical Programs to Key Second Half 2026 Milestones TEL AVIV, Israel, Aug. 17, 2026 (GLOBE... ► Artikel lesen | |
| 28.07. | Nasus Pharma Appoints Brendan O'Grady As CEO, Succeeding Dan Teleman | 1 | RTTNews | ||
| 28.07. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 28.07. | Nasus Pharma names Brendan O'Grady as new CEO | 1 | Investing.com | ||
| 28.07. | Nasus Pharma, Ltd.: Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth | 299 | GlobeNewswire (Europe) | TEL AVIV, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of... ► Artikel lesen | |
| 09.06. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 09.06. | Nasus Pharma reports positive preclinical data for NS003 | 1 | Investing.com | ||
| 26.05. | Nasus Pharma Ltd - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EYEPOINT | 2,760 | -4,83 % | XFRA PV3B: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 38,650 | -0,21 % | Nektar Therapeutics: New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 | Rezpegaldesleukindemonstrateddurabilityanddeepeningofresponsethroughone year of treatment in two dermatological indications, reinforcing the differentiated properties... ► Artikel lesen | |
| FILANA THERAPEUTICS | 0,891 | +8,00 % | XFRA PX91: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| IRONWOOD PHARMACEUTICALS | 3,240 | 0,00 % | PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential? | ||
| GALECTIN THERAPEUTICS | 3,420 | 0,00 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update | NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and... ► Artikel lesen | |
| NRX PHARMACEUTICALS | 2,570 | -0,58 % | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine | Abbreviated New Drug Application (ANDA) Amendment related to the drug vial for preservative-free ketamine has been reclassified from a Major Amendment to a Minor Amendment.FDA has revised the Generic... ► Artikel lesen | |
| GRACE THERAPEUTICS | 2,050 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -3- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameKYG200801002 CBAK... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 9,230 | -0,43 % | Kazia Therapeutics Limited: Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders | Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to Kazia
SYDNEY, Sept. 22, 2026 /PRNewswire/ -- Kazia Therapeutics... ► Artikel lesen | |
| INMED PHARMACEUTICALS | 1,230 | 0,00 % | InMed Pharmaceuticals Inc. - S-4/A, Registration of securities, business combinations | ||
| ELEDON PHARMACEUTICALS | 2,180 | 0,00 % | Eledon Pharmaceuticals, Inc.: Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society | Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus tacrolimus... ► Artikel lesen | |
| HERON THERAPEUTICS | 0,300 | 0,00 % | HERON THERAPEUTICS, INC. /DE/ - 8-K, Current Report | ||
| INVENTIVA | 3,140 | 0,00 % | INVENTIVA: Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update | Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits1 as of June 30, 2026Cash runway guidance remains unchanged from July 30, 20262Topline results of the Phase 3 NATiV3... ► Artikel lesen | |
| MEDICINOVA | 1,800 | +1,12 % | MediciNova, Inc.: MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) | LA JOLLA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
| MILESTONE PHARMACEUTICALS | 0,810 | +0,02 % | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR | MONTREAL and CHARLOTTE, N.C., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative... ► Artikel lesen | |
| ANBIO BIOTECHNOLOGY | 5,400 | +0,93 % | Anbio Biotechnology - 6-K, Report of foreign issuer |
NASUS PHARMA LTD gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 3,840 Euro und damit -5,19 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NASUS PHARMA LTD finden Sie auf Wallstreet Online.